

09/767578

DEVELOPMENT OF HUMAN MONOCLONAL ANTIBODIES AND USES  
THEREOF

Abstract of the Disclosure

5 The present invention provides a heteromyeloma cell other  
than B6B11, capable of producing a trioma cell when fused  
with a human lymphoid cell, wherein the trioma cell is  
capable of producing a tetroma cell capable of producing  
a monoclonal antibody having specific binding affinity  
10 for an antigen, when fused with a second human lymphoid  
cell, the second human lymphoid cell being capable of  
producing antibody having specific binding affinity for  
the antigen. The invention provides a trioma cell fusion  
partner which does not produce any antibody obtained by  
15 fusing a heteromyeloma cell which does not produce any  
antibody with a human lymphoid cell. The invention  
provides a tetroma cell capable of producing a monoclonal  
antibody having specific binding affinity for an antigen  
obtained by fusing a trioma cell which does not produce  
20 any antibody with a human lymphoid cell capable of  
producing antibody having specific binding affinity for  
the antigen. The invention provides a method of  
producing a monoclonal antibody specific for an antigen  
associated with a condition. The invention provides a  
25 method of identifying an antigen associated with a  
condition using the trioma fusion partner. The invention  
provides a method of diagnosing a condition using the  
trioma fusion partner. The invention provides a method  
for preventing a condition. Compositions and therapeutic  
30 compositions are also provided, using monoclonal  
antibodies produced using the trioma fusion partner.

09767578 "012301"